Efatutazone Free Base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 414004

CAS#: 223132-37-4 (free base)

Description: Efatutazone Free Base is a high-affinity PPARgamma agonist with antineoplastic activity.

Chemical Structure

Efatutazone Free Base
CAS# 223132-37-4 (free base)

Theoretical Analysis

MedKoo Cat#: 414004
Name: Efatutazone Free Base
CAS#: 223132-37-4 (free base)
Chemical Formula: C27H26N4O4S
Exact Mass: 502.1675
Molecular Weight: 502.58
Elemental Analysis: C, 64.53; H, 5.21; N, 11.15; O, 12.73; S, 6.38

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 223132-37-4 (free base)   223132-38-5 (HCl)  

Synonym: Efatutazone Free Base; Inolitazone

IUPAC/Chemical Name: 5-(4-((6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzo[d]imidazol-2-yl)methoxy)benzyl)thiazolidine-2,4-dione


InChi Code: InChI=1S/C27H26N4O4S/c1-15-10-20(11-16(2)25(15)28)35-19-8-9-21-22(13-19)31(3)24(29-21)14-34-18-6-4-17(5-7-18)12-23-26(32)30-27(33)36-23/h4-11,13,23H,12,14,28H2,1-3H3,(H,30,32,33)

SMILES Code: Cc1c(N)c(C)cc(Oc(cc2)cc3c2nc(COc4ccc(CC5SC(NC5=O)=O)cc4)n3C)c1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 502.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Ni J, Zhou LL, Ding L, Zhang XQ, Zhao X, Li H, Cao H, Liu S, Wang Z, Ma R, Wu J, Feng J. Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib-resistant lung adenocarcinoma cells. Cancer Med. 2018 May;7(5):1955-1966. doi: 10.1002/cam4.1440. Epub 2018 Mar 23. PMID: 29573196; PMCID: PMC5943475.

2: Alothman SJ, Wang W, Chao S, Kallakury BV, Díaz-Cruz ES, Furth PA. Differential efatutazone's impact on mammary neoplasia dependent upon Brca1 dose. Endocr Relat Cancer. 2018 Dec 1;25(12):L53-L57. doi: 10.1530/ERC-18-0299. PMID: 30400020; PMCID: PMC6944742.

3: Ferrari SM, Elia G, Ragusa F, Ruffilli I, La Motta C, Paparo SR, Patrizio A, Vita R, Benvenga S, Materazzi G, Fallahi P, Antonelli A. Novel treatments for anaplastic thyroid carcinoma. Gland Surg. 2020 Jan;9(Suppl 1):S28-S42. doi: 10.21037/gs.2019.10.18. PMID: 32055496; PMCID: PMC6995904.

4: Ory V, Kietzman WB, Boeckelman J, Kallakury BV, Wellstein A, Furth PA, Riegel AT. The PPARγ agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ. Breast Cancer Res Treat. 2018 May;169(1):47-57. doi: 10.1007/s10549-017-4649-y. Epub 2018 Jan 19. PMID: 29350308; PMCID: PMC5884724.

5: Molinaro E, Romei C, Biagini A, Sabini E, Agate L, Mazzeo S, Materazzi G, Sellari-Franceschini S, Ribechini A, Torregrossa L, Basolo F, Vitti P, Elisei R. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat Rev Endocrinol. 2017 Nov;13(11):644-660. doi: 10.1038/nrendo.2017.76. Epub 2017 Jul 14. PMID: 28707679.

6: De Leo S, Trevisan M, Fugazzola L. Recent advances in the management of anaplastic thyroid cancer. Thyroid Res. 2020 Nov 24;13(1):17. doi: 10.1186/s13044-020-00091-w. PMID: 33292371; PMCID: PMC7684758.

7: Ni J, Zhou LL, Ding L, Zhao X, Cao H, Fan F, Li H, Lou R, Du Y, Dong S, Liu S, Wang Z, Ma R, Wu J, Feng J. PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway. Exp Cell Res. 2017 Dec 15;361(2):246-256. doi: 10.1016/j.yexcr.2017.10.024. Epub 2017 Oct 26. PMID: 29080795.

8: Smallridge RC, Copland JA, Brose MS, Wadsworth JT, Houvras Y, Menefee ME, Bible KC, Shah MH, Gramza AW, Klopper JP, Marlow LA, Heckman MG, Von Roemeling R. Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial. J Clin Endocrinol Metab. 2013 Jun;98(6):2392-400. doi: 10.1210/jc.2013-1106. Epub 2013 Apr 15. PMID: 23589525; PMCID: PMC3667260.

9: Murakami H, Ono A, Takahashi T, Onozawa Y, Tsushima T, Yamazaki K, Jikoh T, Boku N, Yamamoto N. Phase I study of Efatutazone, an oral PPARγ agonist, in patients with metastatic solid tumors. Anticancer Res. 2014 Sep;34(9):5133-41. PMID: 25202104.

10: Nakles RE, Kallakury BV, Furth PA. The PPARγ agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency. Am J Pathol. 2013 Jun;182(6):1976-85. doi: 10.1016/j.ajpath.2013.02.006. Epub 2013 May 8. PMID: 23664366; PMCID: PMC3668033.